CoChat

Patient‐derived xenografts for individualized care in advanced sarcoma

Open access
Stebbing, Justin, Paz, Keren, Schwartz, Gary K., Wexler, Leonard H., Maki, Robert, Pollock, Raphael E., Morris, Ronnie, Cohen, Richard, Shankar, Arjun, Blackman, Glen, Harding, Victoria, Vasquez, David, Krell, Jonathan, Ciznadija, Daniel, Katz, Amanda, Sidransky, David · 2014 · Cancer
Cited by 156

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard‐of‐care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient‐derived xenografts using a proprietary method (“TumorGrafts”). METHODS: Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment. RESULTS: Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft‐predicted therapy. CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision‐making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted. Cancer 2014;120:2006–2015. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28696

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 156

Metadata

Authors
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., Harding, V., Vasquez, D., Krell, J., Ciznadija, D., Katz, A., & Sidransky, D.
Venue
Cancer
Publisher
Wiley
Published
2014-04-04
Volume
120
Issue
13
Pages
2006-2015
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1506338229
Cited by
156
References
9
FWCI
13.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient‐derived xenografts for individualized care in advanced sarcoma. https://app.cochat.ai/papers/10.1002/cncr.28696
The paper
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., Harding, V., Vasquez, D., Krell, J., Ciznadija, D., Katz, A., & Sidransky, D. (2014). Patient‐derived xenografts for individualized care in advanced sarcoma. Cancer. https://doi.org/10.1002/cncr.28696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.